Month: November 2021

Current Challenges in CGT Manufacturing

Cell and gene therapies (CGTs) have gained increasing traction over recent years, as they address significant unmet clinical needs such as cancer therapies and rare genetic diseases. The hope for CGTs is that they not only become novel therapies for diseases with little to no treatment options, but also that they become curative, enabling replacement of life-long treatments of chronic conditions.